Pengyu Zhang

发表

Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.

Liu-fang Gu, Wang-gang Zhang, Fangxia Wang, 2016, Leukemia research.

Regulation of expression of MLAA-34 gene through transcriptional factors E2F1 and MZF-1.

B. Lei, Wanggang Zhang, Xing-mei Cao, 2019, International journal of clinical and experimental pathology.

Management of cytokine release syndrome related to CAR-T cell therapy

B. Lei, Wanggang Zhang, Liu-fang Gu, 2019, Frontiers of Medicine.

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

B. Lei, Wanggang Zhang, Liu-fang Gu, 2017 .

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study

B. Lei, Wanggang Zhang, Liu-fang Gu, 2016, Medical science monitor : international medical journal of experimental and clinical research.

Detection of serum tumor markers in multiple myeloma using the CLINPROT system

Juan Yang, Wanggang Zhang, A. He, 2012, International Journal of Hematology.

High programmed death 1 expression on T cells in aplastic anemia.

Juan Yang, Wanggang Zhang, A. He, 2017, Immunology letters.

Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes

Wanggang Zhang, Jing Li, Liu-fang Gu, 2014, Medical Oncology.

Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL‐17

B. Lei, Yong Yu, Huan Yao, 2019, European journal of pharmacology.

The anti-apoptosis effect of MLAA-34 in leukemia and the β-catenin/T cell factor 4 protein pathway.

B. Lei, Wanggang Zhang, Xiu-lian Wang, 2015, American journal of translational research.

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Saijuan Chen, Hua Jiang, Jian-yong Li, 2022, Journal of Hematology & Oncology.

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

B. Lei, Y. Geng, Zong-fang Li, 2018, Journal of Hematology & Oncology.

Long non-coding RNA RPPH1 promotes the proliferation, invasion and migration of human acute myeloid leukemia cells through down-regulating miR-330-5p expression

B. Lei, Wanggang Zhang, Xing-mei Cao, 2019, EXCLI journal.

Identification and expression of MMSA-8, and its clinical significance in multiple myeloma

Junhui Li, Wanggang Zhang, Jie Liu, 2017, Oncology reports.

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

B. Lei, Liu-fang Gu, Fangxia Wang, 2020 .

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Zong-fang Li, B. Lei, Y. Geng, 2018, Blood.

Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technology

Yang Zhang, Wanggang Zhang, A. He, 2017, Oncotarget.

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Yang Zhang, Juan Yang, Wanggang Zhang, 2014, Proteome Science.

Targeted silencing of genes related to acute monocytic leukaemia by CpG(B)-MLAA-34 siRNA conjugates

Wanggang Zhang, A. He, Xiao-rong Ma, 2019, Journal of drug targeting.

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

B. Lei, Y. Geng, Zong-fang Li, 2019, Blood.

Leukemia-associated gene MLAA-34 reduces arsenic trioxide-induced apoptosis in HeLa cells via activation of the Wnt/β-catenin signaling pathway

B. Lei, Wanggang Zhang, Yin-xia Chen, 2017, PloS one.

C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia

B. Lei, Xin Meng, Wanggang Zhang, 2017, Oncology letters.

Effects of CpG oligodeoxynucleotides on the differentiation of Treg/Th17 cells.

B. Lei, Yuqiang Ji, Wanggang Zhang, 2021, Molecular immunology.

MLAA-34 knockdown shows enhanced antitumor activity via JAK2/STAT3 signaling pathway in acute monocytic leukemia

Yanping Zhang, B. Lei, Xin Meng, 2020, Journal of Cancer.

PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6

R. Liu, A. He, G. Kong, 2023, Cell death & disease.

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Liu-fang Gu, Fangxia Wang, Xing-mei Cao, 2022, Journal of Medical Case Reports.